&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-13, 22:00

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-11-09, 02:51

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition
Monique Kunkel

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-01, 00:51

CORRECTION: The Global Virus Network Bolsters Multinational Mpox Response Through Critical Meeting of Key Global Partners

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-29, 22:48

The Global Virus Network Bolsters Multinational Mpox Response Through Critical Meeting of Key Global Partners
Tony Loman

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-18, 05:45

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
Tamika Gonzalez

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-09, 07:00

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Dora Legere

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-12-11, 20:00

AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-09-18, 17:00

AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
Bradley Crotty

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-07-03, 08:15

Aztiq and Innobic Announce Pricing of Secondary Sale of Lotus Common Stock by AEMH

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-06-05, 18:00

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

Popular Posts